That was one of mine Phlipper...felt I knew the response to the diabetes lead as being too large and out of scope for what is essentially an orphan drug business, but metabolic syndrome is an interesting addition to the possible method of action for 2591.
There could be value down that pathway.
Ann: Neuren approaching transforming milestones in 2021, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
-0.360(2.29%) |
Mkt cap ! $1.938B | |||
| Open | High | Low | Value | Volume |
| $15.80 | $15.80 | $15.19 | $6.795M | 439.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2167 | $15.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.45 | 1494 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |